Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8197308 | 0.93 | XIAP (0.32) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL8187946 | 0.93 | DPP4 (0.30) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL8178947 | 0.91 | CYP3A4 (0.36) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL8190905 | 0.91 | ALDH1A1 (0.32) | KMT2AMEN1ALDH1A1DPP4FAP | |
| SCHEMBL8190778 | 0.91 | TDP1 (0.34) | KMT2ADPP4FAPDPP8DPP9 | |
| SCHEMBL8195302 | 0.90 | KDM4E (0.32) | ALDH1A1DPP4FAPDPP8DPP9 | |
| SCHEMBL13336408 | 0.90 | DPP8 (0.36) | ALDH1A1DPP4FAPDPP8DPP9 | |
| SCHEMBL8196647 | 0.88 | EPHX2 (0.37) | KMT2AMEN1EPHX2 | |
| SCHEMBL8192435 | 0.88 | GAA (0.35) | THRBKMT2AMEN1 | |
| SCHEMBL8192438 | 0.87 | FAP (0.34) | ALDH1A1DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120716-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120716-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2008070733-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120716-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, HPN, PEPD | THRB 3567/4885KMT2A 4160/4885MEN1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.